GlassScriptPhysician profile
Paul C Harrison
NPI 1780811158
$7,270.51
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $799 · 2021: $1,134 · 2022: $2,611 · 2023: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,750 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,750.00 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teladoc Health, INC. | $2,150.00 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $1,784.42 | 2022 | |
| Novo Nordisk INC | $583.99 | 2019-2022 | |
| Lilly USA, LLC | $462.90 | 2019-2022 | |
| Abbvie INC. | $359.40 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $216.53 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $214.29 | 2019-2022 | |
| Pfizer INC. | $178.93 | 2019-2021 | |
| Allergan, INC. | $166.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.15 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $140.87 | 2019-2022 | |
| Amgen INC. | $93.51 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $93.30 | 2021 | |
| Medtronic, INC. | $89.84 | 2022 | |
| Abbott Laboratories | $88.61 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $64.20 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $59.51 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.12 | 2020-2021 | |
| Sanofi Pasteur INC. | $46.65 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.57 | 2019-2020 | |
| Glaxosmithkline, LLC. | $41.76 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $39.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.31 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $27.52 | 2020 | |
| Upsher-Smith Laboratories LLC | $18.99 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.36 | 2022 | |
| Ibsa Pharma INC. | $15.88 | 2020 | |
| Aytu Biopharma, INC. | $14.70 | 2019 | |
| Vivus LLC | $12.76 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.